Danaher Co. (NYSE:DHR) Shares Sold by Founders Financial Securities LLC

Founders Financial Securities LLC trimmed its position in Danaher Co. (NYSE:DHR) by 43.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 860 shares of the conglomerate’s stock after selling 654 shares during the quarter. Founders Financial Securities LLC’s holdings in Danaher were worth $215,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC lifted its stake in Danaher by 20.2% in the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after purchasing an additional 1,533 shares in the last quarter. First Citizens Bank & Trust Co. raised its position in shares of Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after buying an additional 149 shares during the period. Cercano Management LLC raised its position in shares of Danaher by 11.4% during the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after buying an additional 20,715 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after buying an additional 96,395 shares during the period. Finally, Caden Capital Partners LP raised its position in shares of Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after buying an additional 15,313 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Over the last quarter, insiders sold 148,783 shares of company stock worth $37,536,717. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of several analyst reports. Bank of America lifted their price target on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Barclays lifted their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. TD Cowen boosted their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Citigroup boosted their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Finally, Robert W. Baird boosted their target price on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Danaher Stock Performance

NYSE:DHR opened at $249.85 on Monday. The company has a fifty day simple moving average of $255.96 and a two-hundred day simple moving average of $246.75. The company has a market cap of $185.06 billion, a price-to-earnings ratio of 42.35, a price-to-earnings-growth ratio of 3.82 and a beta of 0.85. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $269.11.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.36 earnings per share. As a group, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s payout ratio is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.